Halberd Corporation: Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
JACKSON CENTER, PA / ACCESSWIRE / June 1, 2021 / Halberd Corporation (OTC PINK:HALB) announced the filing of a U. S. joint provisional patent application titled, Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2. The innovation is a result of Halberd s Sponsored Research conducted at Arizona State University (ASU). The provisional patent application covers technology developed to facilitate conjugation of metallic nanoparticles with antibodies against various bacteria and SARS-CoV-2, for elimination via radio waves. Additionally, the patent discloses the use of such a conjugated moiety as a means of detecting the presence and level of the SARS-CoV-2 viral load in a patient.
Breakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy JACKSON CENTER, PA / ACCESSWIRE / May 25, 2021 / Halberd Corporation (OTC
JACKSON CENTER, PA / ACCESSWIRE / May 19, 2021 / Halberd Corporation (OTC PINK:HALB) was featured in a recent
MarketWatch article, New Approaches to Covid-19 Treatment Enter the Picture, along with six other notable biotechnology companies. As stated in the article, The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (PFE), BioNTech SE - ADR (BNTX), Moderna Inc (MRNA), AstraZeneca plc (NAZN), Novavax Inc (NVAX), Halberd Corp (OTC PINK:HALB), and Johnson & Johnson (JNJ).
The article goes on to recognize Halberd for its innovative approach - using radio waves or laser emissive energy, extracorporeally, to eradicate the SARS-CoV-2 virus from bodily fluids, stating, The company [Halberd] may be one of the few that has the capacity to offer something materially different to the established paradigm.
Halberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal Antibody finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Halberd Corporation Begins Testing of Patented Process for Laser Eradication of Disease
JACKSON CENTER, PA / ACCESSWIRE / May 13, 2021 / Halberd Corporation (OTC PINK:HALB) announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease. This technology facilitates disease eradication without the side-effects normally associated with conventional internal medications. The experimentation is now being conducted at Youngstown State University (YSU) under the direct supervision of Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences (PAGES) Department. Initial experiments using the laser are intended to calibrate optimum laser wave length and pulse duration exposure. YSU currently has four different lasers available from which to select the best emissive energy power source.